Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DuACT (Ribavirin + Nitazoxanide) in COVID-19
NCT04563208Phase 2Completed
- Sponsor
- University of the Witwatersrand
- Start
- Dec 2020
- Primary completion
- Feb 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of ribavirin, nitazoxanide in coronavirus disease 2019 (COVID-19), sponsored by University of the Witwatersrand. Started Dec 2020; status: completed.
02
Drugs
ribavirinnitazoxanide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04563208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563208.